Q2 FY27: consolidated revenue up 14%, profit after tax up 33%, EBITDA margin expands
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 ended September 30, 2026: revenue from operations rose 14% to Rs 2,909.94 crore from Rs 2,556.50 crore, and profit after tax attributable to owners rose 33% to Rs 375.13 crore from Rs 282.57 crore. EBITDA margin rose to 22.97% from 21.68%; a Rs 24.26 crore claim was booked as an exceptional item. Consolidated H1: revenue Rs 5,698.04 crore, up 17%; profit after tax Rs 777.02 crore, up 51%. The auditor review was unmodified.
Positive: revenue and profit grew in Q2 and EBITDA margin expanded, supporting earnings sentiment despite the Rs 24.26 crore claim provision.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.